|
|
|
|
|
Ellence: profile and news
Addition of Ellence® to Standard Chemotherapy Does Not Improve ... Mar 2, 2006 Genta Appoints Seasoned Pharma Executive, Lloyd Sanders, as Vice ... Jan 17, 2006 Pfizer Fourth-Quarter and Full-Year 2005 Financial Results Reflect ... Jan 19, 2006 Taxol®, Ifex® and Platinol® Effective Second-Line Therapy for ... Sep 22, 2005 Many meds don't mix with the sun Sep 21, 2005 The search is on for New Zealand’s first Pet Idol Sep 1, 2005 Pfizer seeks approval for cancer drug Aug 10, 2005 Xeloda® and Radiation Therapy Effective for Elderly and ... Aug 3, 2005 DePalma leads Georgeotwn to its highest seeding in Big East ... Aug 4, 2005 Less Toxic Adjuvant Chemotherapy Regimen for Patients with Locally ... Jul 29, 2005 Pfizer Inc Second-Quarter 2005 Performance Report Jul 20, 2005 Less Toxic Adjuvant Chemotherapy Regimen for Patients with Locally ... Jul 25, 2005 Higher Cumulative Doses of Epirubicin and Cyclophosphamide for ... Jun 27, 2005 Higher Cumulative Doses of Epirubicin and Cyclophosphamide for ... 13 Sep 2002 FDA Safety Labeling Changes: Ellence, Abilify, Kaletra Jun 1, 2005 25 jobs to go at Cork pharmaceutical plants Jun 7, 2005 Combination Chemotherapy in Addition to Gemzar® Improves Survival ... Jun 6, 2005 Pfizers invest €100m in plant Jun 8, 2005 DePalma leads Georgeotwn to its highest seeding in Big East ... Jun 8, 2005 Pfizer Inc First-Quarter 2005 Performance Report Apr 19, 2005 /SECOND AND FINAL ADD -- NYTU041B -- Pfizer Inc Earnings/ Apr 19, 2005 Court rules against Mayne generic Feb 18, 2005 Gleevec® Promising for AIDS-Related Kaposi’s Sarcoma Feb 15, 2005 Other information Indication For use as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer Pharmacology Epirubicin is an antineoplastic in the anthracycline class. General properties of drugs in this class include: interaction with DNA in a variety of different ways including intercalation (squeezing between the base pairs), DNA strand breakage and inhibition with the enzyme topoisomerase II. Most of these compounds have been isolated from natural sources and antibiotics. However, they lack the specificity of the antimicrobial antibiotics and thus produce significant toxicity. The anthracyclines are among the most important antitumor drugs available. Doxorubicin is widely used for the treatment of several solid tumors while daunorubicin and idarubicin are used exclusively for the treatment of leukemia. Epirubicin may also inhibit polymerase activity, affect regulation of gene expression, and produce free radical damage to DNA. Epirubicin possesses an antitumor effect against a wide spectrum of tumors, either grafted or spontaneous. The anthracyclines are cell cycle-nonspecific. Mechanism Of Action Epirubicin has antimitotic and cytotoxic activity. It inhibits nucleic acid (DNA and RNA) and protein synthesis through a number of proposed mechanisms of action: Epirubicin forms complexes with DNA by intercalation between base pairs, and it inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, preventing the religation portion of the ligation-religation reaction that topoisomerase II catalyzes. It also interferes with DNA replication and transcription by inhibiting DNA helicase activity. Drug Category Antineoplastic Agents; ATC:L01DB03 Brand Names/Synonyms 4'-Epiadriamycin; 4'-Epidoxorubicin; CCRIS 2261; Ellence; Epi-Dx; Epiadriamycin; Epidoxorubicin; Epirubicin; Epirubicina [Inn-Spanish]; Epirubicina [Spanish]; Epirubicine [French]; Epirubicine [Inn-French]; Epirubicinum [Inn-Latin]; Epirubicinum [Latin]; HSDB 6962; IMI 28; Pharmorubicin Pfs; Pidorubicina [Inn-Spanish]; Pidorubicine [Inn-French]; Pidorubicinum [Inn-Latin]; Ridorubicin; WP 697 Dosage Forms POWDER FOR SOLUTION; SOLUTION Absorption 100% Interactions -->Interactions for Epirubicin: ELLENCE when used in combination with other cytotoxic drugs may show on-treatment additive toxicity, especially hematologic and gastrointestinal effects. Concomitant use of ELLENCE with other cardioactive compounds that could cause heart failure (e.g., calcium channel blockers), requires close monitoring of cardiac function throughout treatment. There are few data regarding the coadministration of radiation therapy and epirubicin. In adjuvant trials of epirubicin-containing CEF-120 or FEC-100 chemotherapies, breast irradiation was delayed until after chemotherapy was completed. This practice resulted in no apparent increase in local breast cancer recurrence relative to published accounts in the literature. A small number of patients received epirubicin-based chemotherapy concomitantly with radiation therapy but had chemotherapy interrupted in order to avoid potential overlapping toxicities. It is likely that use of epirubicin with radiotherapy may sensitize tissues to the cytotoxic actions of irradiation. Administration of ELLENCE after previous radiation therapy may induce an inflammatory recall reaction at the site of the irradiation. Epirubicin is extensively metabolized by the liver. Changes in hepatic function induced by concomitant therapies may affect epirubicin metabolism, pharmacokinetics, therapeutic efficacy, and/or toxicity. Cimetidine increased the AUC of epirubicin by 50%. Cimetidine treatment should be stopped during treatment with ELLENCE. Drug-Laboratory Test Interactions There are no known interactions between ELLENCE and laboratory tests. Chemical IUPAC Name 10-(4-amino-5-hydroxy-6-methyl-oxan-2-yl)oxy-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-9,10-dihydro-7H-tetracene-5,12-dione Chemical Formula C27H29NO11 Half Life half-lives for the alpha, beta, and gamma phases of about 3 minutes, 2.5 hours and 33 hours, respectively Drug Type Approved Drug # Accession No APRD00361 CAS Registry Number 56420-45-2 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |